Gossamer Bio, Inc. — SEC Form D Filing

Gossamer Bio, Inc. filed an SEC Form D on September 4, 2026, reporting $25.00M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
September 4, 2026
Amount reported
$25.00M
Round stage
Series B+
Industry
Biotechnology
Website
https://www.gossamerbio.com/

What the company does

Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

People suffer from rare diseases such as pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Solution

Gossamer Bio is developing seralutinib, an investigational inhaled PDGFRα/β, CSF1R, and c‑KIT inhibitor delivered via a dry powder inhaler, for the treatment of PAH and PH-ILD.

Why now

Advances in understanding specific disease pathways and the development of targeted therapies for rare diseases allow for the creation of new, potentially life-changing treatments.

Verdict

Investors backed this because the narrative offered a clear de-risking pathway in a high-value rare disease segment, positioning Gossamer Bio for a potential acquisition or accelerated approval. This cleared because of the established regulatory and commercial precedent for rare disease assets, not because of novel platform technology. The implicit bet was on clinical trial success and market exclusivity, which simultaneously limited upside by tying valuation tightly to a single asset's performance rather than a broader pipeline.

Source: SEC EDGAR Form D filing